(Q42644898)

4 November 2017

0 references

Five-year efficacy and safety of levodopa/DDCI and entacapone in patients with Parkinson's disease (English)

1 reference

4 November 2017

1 reference

1

1 reference

4 November 2017

Mika Leinonen

2

1 reference

4 November 2017

Mikko Kuoppamäki

series ordinal

3

1 reference

4 November 2017

Helena Nissinen

series ordinal

4

1 reference

4 November 2017

publication date

8 February 2008

1 reference

Journal of Neural Transmission

4 November 2017

published in

1 reference

4 November 2017

volume

115

1 reference

4 November 2017

issue

6

1 reference

4 November 2017

page(s)

843-849

1 reference

https://scigraph.springernature.com/pub.10.1007/s00702-008-0025-8

4 November 2017

exact match

0 references

cites work

Progression of motor impairment and disability in Parkinson disease: a population-based study.

1 reference

https://api.crossref.org/works/10.1007%2FS00702-008-0025-8

The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-008-0025-8

Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-008-0025-8

Differential progression of motor impairment in levodopa-treated Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-008-0025-8

The tolerability and efficacy of entacapone over 3 years in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-008-0025-8

Twelve-month safety of entacapone in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-008-0025-8

Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-008-0025-8

Levodopa in the treatment of Parkinson's disease: current controversies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-008-0025-8

Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-008-0025-8

Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-008-0025-8

Levodopa prolongs life expectancy and is non-toxic to substantia nigra

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-008-0025-8

A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-008-0025-8

The levodopa wearing-off phenomenon in Parkinson's disease: pharmacokinetic considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-008-0025-8

21 January 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/18259682

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18259682

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18259682

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00702-008-0025-8

1 reference

4 November 2017

1 reference